{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:53Z","timestamp":1783423133491,"version":"3.54.6"},"reference-count":48,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Skeletal safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains uncharted, with emerging evidence suggesting a divergence between mono- and dual-agonist therapies. GLP-1RA monotherapy appears bone-neutral, with modest or no adverse effects on bone mineral density (BMD), whilst dual agonists may confer a relatively higher risk of osteoporosis and fractures, plausibly mediated by greater weight loss magnitude and concomitant reductions in lean body mass (LBM) rather than direct osteotoxicity. Intensified surveillance is warranted in susceptible phenotypes, including older adults and postmenopausal women with low baseline BMD under conditions of rapid weight loss. Osteoporosis risk is further amplified by pre-existing osteopenia, nutritional deficiencies, and concomitant exposure to bone-active agents. Given the limitations of serial dual-energy X-ray absorptiometry (DXA), including cumulative radiation exposure and limited sensitivity to early remodeling changes, biochemical markers potentially depict bone turnover more dynamically. Measurement of dynamic bone resorption markers enables early identification of skeletal disturbances, supporting proactive adjustment of therapeutic strategy, dosing, and duration. Specifically, deoxypyridinoline (DPD), a bone-specific collagen crosslink, is a highly sensitive and rapidly responsive urine biomarker of osteoclastic activity. Incorporating DPD urine testing into monitoring frameworks potentially facilitates individualized therapeutic modulation, optimizing the metabolic efficacy of GLP-1RAs while safeguarding skeletal integrity.<\/jats:p>","DOI":"10.3390\/diagnostics16132128","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:53:46Z","timestamp":1783418026000},"page":"2128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0798-6262","authenticated-orcid":false,"given":"Angeliki","family":"Margoni","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthimia K.","family":"Basdra","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-4527","authenticated-orcid":false,"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.clnu.2023.10.013","article-title":"The effect of overweight or obesity on osteoporosis: A systematic review and meta-analysis","volume":"42","author":"Liu","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40519-018-0505-2","article-title":"The obesity paradox and osteoporosis","volume":"23","author":"Fassio","year":"2018","journal-title":"Eat. Weight Disord."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Luo, Q., Zhang, S., Liang, Z., Wang, D., Zhong, Y., Xia, B., Xie, P., Wang, C., Yuan, J., and Zhang, Z. (2025). The obesity paradox in osteoporosis risk among older adults is mostly driven by women: A population-based prospective study. BMC Geriatr., 25.","DOI":"10.1186\/s12877-025-05704-3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11914-024-00867-1","article-title":"Diagnosing osteoporosis in diabetes\u2014A systematic review on BMD and fractures","volume":"22","author":"Brandt","year":"2024","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40200-024-01474-8","article-title":"Assessment of fracture risk in diabetic patients","volume":"23","author":"Wang","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ma, X., and Zhang, X. (2025). Research progress of diabetic osteoporosis: A comprehensive review. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1595228"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"116159","DOI":"10.1016\/j.bone.2021.116159","article-title":"Glucose variability and low bone turnover in people with type 2 diabetes","volume":"153","author":"Lykkeboe","year":"2021","journal-title":"Bone"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100330","DOI":"10.1016\/j.metop.2024.100330","article-title":"Understanding the impact of diabetes on bone health: A clinical review","volume":"24","author":"Sharma","year":"2024","journal-title":"Metab. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6640796","DOI":"10.1155\/2024\/6640796","article-title":"Potential metabolic pathways involved in osteoporosis and evaluation of fracture risk in individuals with diabetes","volume":"2024","author":"Liu","year":"2024","journal-title":"Biomed. Res. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1530\/EJE-16-0652","article-title":"Diabetes mellitus, a state of low bone turnover\u2014A systematic review and meta-analysis","volume":"176","author":"Hygum","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez, B.R., Rodr\u00edguez de Vera G\u00f3mez, P., Belmonte Lomas, S., Mesa D\u00edaz, \u00c1.M., Caballero Mateos, I., Gal\u00e1n, I., Morales Portillo, C., and Mart\u00ednez-Brocca, M.A. (2024). Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1386542"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12777","article-title":"Glucagon-like peptide-1(GLP-1) receptor agonists: Potential to reduce fracture risk in diabetic patients?","volume":"81","author":"Luo","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1785321","DOI":"10.1155\/2024\/1785321","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"2024","author":"Li","year":"2024","journal-title":"Int. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lv, F., Cai, X., Lin, C., Yang, W., and Ji, L. (2024). Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121655"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-018-1001-2","article-title":"RANKL\/RANK\/OPG system beyond bone remodeling: Involvement in breast cancer and clinical perspectives","volume":"38","author":"Infante","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_20","first-page":"e89020","article-title":"Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review","volume":"17","author":"Hong","year":"2025","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): A post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112995","DOI":"10.1016\/j.diabres.2025.112995","article-title":"Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database","volume":"230","author":"Hsu","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1210\/clinem\/dgag056","article-title":"GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes","volume":"111","author":"Twig","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: A review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjms.2024.08.024","article-title":"Medication-induced fractures: Screening and treatment strategies","volume":"369","author":"Javed","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: Recommendations from the European Calcified Tissue Society","volume":"191","author":"Paccou","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109440","DOI":"10.1016\/j.steroids.2024.109440","article-title":"A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease","volume":"207","author":"Rahman","year":"2024","journal-title":"Steroids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.biocel.2006.11.017","article-title":"Breast cancer: The upgraded role of HER-3 and HER-4","volume":"39","author":"Karamouzis","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kilroy, M.K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., and Garrett, J.T. (2022). HER3 alterations in cancer and potential clinical implications. Cancers, 14.","DOI":"10.3390\/cancers14246174"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11657-025-01588-3","article-title":"The 2024 UK clinical guideline for the prevention and treatment of osteoporosis","volume":"20","author":"Gregson","year":"2025","journal-title":"Arch. Osteoporos."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00259-024-06912-6","article-title":"Updated practice guideline for dual-energy X-ray absorptiometry (DXA)","volume":"52","author":"Slart","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","first-page":"329","article-title":"Bone microarchitecture assessed by 3D high-resolution peripheral quantitative computed tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis","volume":"51","author":"So","year":"2025","journal-title":"J. Orthop. Transl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhang, Y., Liu, X., Chen, B., and Lei, L. (2024). Effect of type 2 diabetes on biochemical markers of bone metabolism: A meta-analysis. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1330171"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","article-title":"Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: A consensus paper from ESCEO, IOF and IFCC","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos. Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wu, S., Wang, L., Zhang, X., Cai, L., Ke, Q., and Xu, J. (2026). Bone turnover markers (\u03b2-CTX, PINP, ALP) in osteoporosis: Correlation with bone loss and fracture risk stratification. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1628434"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127772","DOI":"10.52965\/001c.127772","article-title":"The treatment and monitoring of osteoporosis using bone turnover markers","volume":"17","author":"Patel","year":"2025","journal-title":"Orthop. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Leszczy\u0144ska, D., \u0141abu\u015b, W., Zgliczy\u0144ski, W., G\u0142uszko, P., Krela-Ka\u017amierczak, I., G\u0142uszko, A., Laskowska, K., Krajewski, P., G\u00f3rska, M., and Kania, E. (2025). Novel aspects of biochemical assessment of bone remodeling and mineralization. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1702413"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bone.2015.08.014","article-title":"Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site","volume":"81","author":"Kim","year":"2015","journal-title":"Bone"},{"key":"ref_42","first-page":"2447","article-title":"Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients","volume":"80","author":"Kushida","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","first-page":"1136","article-title":"Reference value for urinary deoxypyridinoline as a specific marker for measuring bone resorption in Thais","volume":"82","author":"Pidetcha","year":"1999","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/v10039-009-0003-x","article-title":"Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes","volume":"54","author":"Fassbender","year":"2009","journal-title":"Adv. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00198-009-1108-6","article-title":"Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid","volume":"21","author":"Kaji","year":"2010","journal-title":"Osteoporos. Int."},{"key":"ref_46","first-page":"217","article-title":"Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: Advantage of free form of DPD over total DPD in predicting treatment efficacy","volume":"21","author":"Kitatani","year":"2003","journal-title":"J. Bone Miner. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0009-9120(01)00269-7","article-title":"Variability in urinary excretion of bone resorption markers: Limitations of a single determination in clinical practice","volume":"34","author":"Borderie","year":"2001","journal-title":"Clin. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/jbmr.5650091019","article-title":"Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption","volume":"9","author":"Robins","year":"1994","journal-title":"J. Bone Miner. Res."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:00:40Z","timestamp":1783422040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":48,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16132128"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16132128","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}